Johnson & Johnson is repositioning itself as a medical innovation powerhouse, with management now emphasizing its pharmaceutical ambitions over the broader health care label it once used. Innovative Medicine generates about $60 billion annually, roughly 64% of revenue, and grew 6.8% in the latest quarter, while the MedTech segment, at about $34 billion, grew 3.6%. The company plans to separate its orthopedics business by mid-2027, even though that unit grew 4.2% last quarter, while cardiovascular, which will remain, grew only 3.1% and saw its Abiomed heart-recovery business decline 2%. Despite the shift, Johnson & Johnson raised its full-year operational sales growth guidance to 6.5% to 7.1%, implying sales of about $100.6 billion.
Johnson & Johnsonraised full-year operational sales growth guidance to 6.5%-7.1%, implying ~$100.6B sales
AbbVie Inc
Eli Lilly and Company
Pfizer Inc